Form 4: Bio-Rad Laboratories Executive Acquires Stock Options

Simon May, EVP and President of Life Science Group at Bio-Rad Laboratories, acquired 3,535 non-qualified stock options on March 8, 2024.

Summary

• Simon May, an executive at Bio-Rad Laboratories, acquired 3,535 non-qualified stock options on March 8, 2024.
• The exercise price of these options is $343.76.
• The options vest over four years, with 25% vesting each year on the anniversary of the grant date.
• The expiration date for these options is March 8, 2034.
• Following the transaction, May directly owns 3,535 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The acquisition of stock options by an executive is generally viewed as a sign of confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of stock options by a high-ranking executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Thermo Fisher Scientific and Danaher also utilize stock options to incentivize their executives.
• The vesting schedule of four years with 25% vesting annually is a typical arrangement.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates